Yahoo
NSE - Delayed Quote INR

Thyrocare Technologies Limited (THYROCARE.NS)

456.30 -59.20 (-11.48%)
At close: October 30 at 3:30:00 PM GMT+5:30
Chart Range Bar
Loading chart for THYROCARE.NS
  • Previous Close 515.50
  • Open 496.05
  • Bid --
  • Ask --
  • Day's Range 445.30 - 503.50
  • 52 Week Range 342.55 - 662.00
  • Volume 6,050,227
  • Avg. Volume 572,671
  • Market Cap (intraday) 72.627B
  • Beta (5Y Monthly) 0.45
  • PE Ratio (TTM) 50.87
  • EPS (TTM) 8.97
  • Earnings Date (est.) --
  • Forward Dividend & Yield 9.33 (2.05%)
  • Ex-Dividend Date Jun 23, 2026
  • 1y Target Est 681.00

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.

www.thyrocare.com

1,906

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

THYROCARE.NS
3.71%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

THYROCARE.NS
2.93%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

THYROCARE.NS
168.82%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

THYROCARE.NS
34.25%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY27
Revenue 2.71B
Earnings 158.9M
Profit Margin 5.87%

Q3

FY26

Q4

FY26

Q1

FY27

Q2

FY27

0
500M
1B
2B
2B
3B
0.0%
5.0%
10.0%
15.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

615.00
681.00 Average
456.30 Current
730.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.13%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    8.76B

  • Net Income Avi to Common (ttm)

    1.76B

  • Diluted EPS (ttm)

    8.97

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.9B

  • Total Debt/Equity (mrq)

    8.65%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: